BNTC
Benitec Biopharma Ltd ADR
NASDAQ: BNTC · HEALTHCARE · BIOTECHNOLOGY
$11.84
-4.52% today
Updated 2026-06-05
Market cap
$362.44M
P/E ratio
—
P/S ratio
2,770.13x
EPS (TTM)
$-0.93
Dividend yield
—
52W range
$10 – $17
Volume
0.1M
WallStSmart proprietary scores
32
out of 100
Grade: F
Strong Sell
Investment rating
5.0
Growth
C+8.5
Quality
A3.0
Profitability
D5.0
Valuation
C+3/9
Piotroski F-Score
Weak
22.0
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$24.33
+105.49%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 21.99 — safe zone
+ Revenue growth 12.50% QoQ
+ Debt/equity 0.00x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-4.93M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $73000.00 | $75000.00 | $216000.00 | $0.00 | $7000.00 |
| Net income | $-18.21M | $-19.56M | $-21.75M | $-37.92M | $-11.94M |
| EPS | — | — | — | — | $-0.93 |
| Free cash flow | $-15.91M | $-18.01M | $-19.58M | $-23.61M | $-4.93M |
| Profit margin | -24,942.47% | -26,082.67% | -10,069.91% | — | — |
Peer comparison
Smart narrative
Benitec Biopharma Ltd ADR trades at $11.84. Our Smart Value Score of 32/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 21.99, it sits in the safe zone. TTM revenue stands at $7000.00.
Frequently asked questions
What is Benitec Biopharma Ltd ADR's stock price?
Benitec Biopharma Ltd ADR (BNTC) trades at $11.84, on a P/S of 2,770.1x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Benitec Biopharma Ltd ADR overvalued?
Benitec Biopharma Ltd ADR carries a Smart Value Score of 32/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Benitec Biopharma Ltd ADR (BNTC)?
The 12-month analyst consensus target is $24.33, about 105.5% above the current $11.84. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Benitec Biopharma Ltd ADR's revenue?
Benitec Biopharma Ltd ADR's trailing twelve-month revenue is $7000.00. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Benitec Biopharma Ltd ADR's Altman Z-Score is 21.99, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio2,770.13x
ROE-26.66%
Beta0.28
50D MA$11.73
200D MA$12.67
Shares out0.03B
Float0.02B
Short ratio—
Avg volume0.1M
Performance
1 week-3.58%
1 month-12.94%
3 months+14.07%
YTD-12.10%
1 year—
3 years—
5 years—